Innovative patient stability technology developed at MCIRCC gets FDA market approval
This is an article about portfolio company, Fifth Eye Inc.
The Michigan Medicine spinoff company received an $11.5 million Series A investment for the product nearly two years ago.
A medical device that works to detect if a patient will become unstable earlier than traditional vital signs received the green light to be marketed to U.S. hospitals.
Fifth Eye Inc., a Michigan Medicine spinoff medical device software company founded in 2017, was recently granted FDA De Novo classification for its Analytic for Hemodynamic Instability (AHI). The noninvasive device continuously monitors electrocardiogram (ECG) signals to identify signs of hemodynamic decline.
View source version on uofmhealth.org: https://www.uofmhealth.org/news/archive/202103/innovative-patient-stability-technology-developed-m